profile picture of Jim Krenn

Jim Krenn

Partner | San Diego

I provide strategic advice to help clients achieve their business objectives in major corporate transactions.


Represented this medical instruments company in its sale to Agilent Technologies (NYSE: A) for $250 million.

Represented this parent company of a regulated electric utility in Alaska in its $170 million sale to Avista (NYSE: AVA).

Represented this medical diagnostic company focused on high-risk medical conditions and diseases in its $90 million sale to bioMérieux (EPA: BIM).

Represented this diversified financial services company in its $53 million private placement and merger with investment banking firm B. Riley & Co.

Represented this private equity-backed developer and manufacturer of laboratory consumables and liquid handling solutions in its sale to Mettler-Toledo (NYSE: MTD) for an undisclosed sum.

Represented this private equity-backed leader in reproductive tissue donor services and stem cell banking in multiple acquisitions.

Represented this provider of natural gas as an alternative fuel for vehicle fleets in its sale for up to $180 million of components of its renewable natural gas business to BP (NYSE: BP).

Represented this biometric identification solutions provider in its $943 million sale to 3M (NYSE: MMM).

Represented this agricultural, construction, and forestry machinery corporation in its announced acquisition of the precision planning unit of Monsanto (NYSE: MON) for an undisclosed sum.

Represented this leading supplier of medical products for the global aesthetic market in its $1.12 billion sale to Johnson & Johnson (NYSE: JNJ).

Named Life Sciences Star in Mergers & Acquisitions

Legal Media Group 2022

Named Life Sciences Star in Venture Capital

Legal Media Group 2022